Clinical pharmacology - Providing tools and expertise for translational medicine

British Journal of Clinical Pharmacology

Volumn 65, Issue 2, 2008, Pages 154-157

  Aronson, J K ^a   Cohen, A ^a   Lewis, L D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CYTOCHROME P450 2C9; CYTOTOXIC AGENT; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MENADIONE EPOXIDE; WARFARIN;

CLINICAL PHARMACOLOGY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG INFORMATION; DRUG LABELING; DRUG MECHANISM; ENZYME ACTIVITY; GENETIC VARIABILITY; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; MEDICAL EDUCATION; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL RESEARCH; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY, CLINICAL; PROFESSIONAL COMPETENCE; PROTEIN BIOSYNTHESIS;

EID: 38649113872     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03101.x     Document Type: Review

References (26)

1. Aronson JK. Overate? BMJ 2000 320 : 625.
2. Marincola FM. Translational medicine: a two-way road. J Transl Med 2003 1 : 1.
3. Aronson JK. On the waterfront - the breadth and depth of clinical pharmacology. Br J Clin Pharmacol 2004 57 : 693 4.
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001 409 : 860 921.
5. O'Shaughnessy KM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol 2006 61 : 783 6.
6. Begg EJ. Individualizing drug therapy, and 'men behaving badly'. Br J Clin Pharmacol 2004 58 : 449 51.
7. National Institute for Health Research. The Efficacy and Mechanism Evaluation (EME) programme. http://www.nihr.ac.uk/ programmes_research_programmes_eme.aspx (last accessed 4 January 2008).
8. National Center for Research Resources. Clinical and Translational Science Awards. http://www.ncrr.nih.gov/clinical_research_resources/ clinical_and_translational_science_awards (last accessed 4 January 2008).
9. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies - CYP2C9 and warfarin as an example. Br J Clin Pharmacol 2007 64 : 14 26.
10. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006 62 : 35 46.
11. Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, Myrand SP. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 2007 64 : 458 68.
12. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007 99 : 1290 5.
13. PharmGkb. The pharmacogenetics and pharmacogenomics knowledge database. http://www.pharmgkb.org/search/browse.action?browseKey=pathways (last accessed: 4 January 2008).
14. Rognan D. Chemogenomic approaches to rational drug design. Br J Pharmacol 2007 152 : 38 52.
15. Aronson JK. Biomarkers and surrogate endpoints in monitoring therapeutic interventions. In : Glasziou P, Irwig L, Aronson JK, editors. Evidence-based Medical Monitoring: From Principles to Practice. Oxford : Wiley-Blackwell, 2008.
16. Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol 2005 59 : 491 4.
17. Li KM, Rivory LP, Hoskins J, Sharma R, Clarke SJ. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. Br J Clin Pharmacol 2007 63 : 67 74.
18. Zgheib N K, Frye RF, Tracy TS, Romkes M, Branch RA. Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity. Br J Clin Pharmacol 2007 63 : 477 87.
19. van Doorn M, Vogels J, Tas A, Van Hoogdalem EJ, Burggraaf J, Cohen A, Van der Greef J. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol 2007 63 : 562 74.
20. Wykretowicz A, Guzik P, Krauze T, Adamska K, Milewska A, Wysocki H. Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation. Br J Clin Pharmacol 2007 64 : 792 5.
21. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br J Clin Pharmacol 2007 64 : 591 602.
22. Lönnebo A, Grahnén A, Karlsson MO. An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers. Br J Clin Pharmacol 2007 64 : 125 32.
23. Ndovi TT, Parsons T, Choi L, Caffo B, Rohde C, Hendrix CW. A new method to estimate quantitatively seminal vesicle and prostate gland contributions to ejaculate. Br J Clin Pharmacol 2007 63 : 404 20.
24. Van der Schueren BJ, de Hoon JN, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol 2007 64 : 580 90.
25. Drummond PD. Repeated cycles of electrical stimulation decrease vasoconstriction and axon-reflex vasodilation to noradrenaline in the human forearm. Br J Clin Pharmacol 2007 64 : 421 7.
26. Wellcome Trust. Interdisciplinary Training Programmes for Clinicians in Translational Medicine and Therapeutics. http://www.wellcome.ac.uk/node2165.html (last accessed: 4 January 2008).